HKSTP Teams Up with HKU and CUHK Medical Schools to Showcase Hong Kong’s Life Health Innovations at BIO International Convention
- Written by Hong Kong Science and Technology Parks Corporation
In collaboration with InvestHK, HKSTP joined forces with the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) for the first time to form a delegation and led 16 prominent life and health technology companies to showcase at BIO 2025 held in Boston, USA.
The HKSTP Pavilion highlighted the groundbreaking technologies and products of its park companies, featuring innovative solutions across diverse fields such as novel drug development, diagnostic technologies, and medical innovation. Among the 16 participating companies, they were the members of HKSTP's incubation programmes including Incu-Bio and ELITE Programme, cutting-edge work from the InnoHK research centers, and other outstanding biotech companies. On the first day of the exhibition, the delegation successfully attracted attention from global industry leaders, corporate partners, and venture capital firms.During BIO 2025, HKSTP and its park companies made significant strides in fostering cross-border innovation ecosystems and exploring new market opportunities:
- Immuno Cure, partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX.
- HKSTP signed a partnership agreement with DLRC to provide legal advisory services in clinical trials and certification, promoting global ecosystem collaboration and growth.
Ahead of BIO 2025, the delegation participated in the "2025 Biomedical Pitch Competition", co-organized by the Boston Capital Investment Club (BCIC) and HKSTP. The event connects global life and health innovators with investors and business partners. Three HKSTP companies—ARBELE, GenEditBio, and Cogsmart—excelled in the preliminary rounds, competing against over 100 global life sciences firms, with ARBELE, HKUMed's affiliated spin-off company, winning the championship, underscoring Hong Kong's research excellence. Over the past three years, this platform has helped startups secure over USD 100 million in funding and connect with hundreds of international investors and partners, driving further business growth.
HKSTP is committed to propelling Hong Kong's life sciences sector onto the global stage, showcasing the city's unique strengths to attract international enterprises and talent. The delegation also organized networking events and visits, enabling Hong Kong companies to engage with overseas investors, leading corporations, and renowned academic institutions, including visits to MIT Professor Robert Langer (Described as "Edison of Medicine"), Harvard Innovation Labs, Cambridge Innovation Center, and more. This initiative reinforces Hong Kong's sustainable development in life sciences and its role as a global innovation leader.
Appendix: List of Park Companies Participating in BIO 2025:
- Allegrow Biotech Limited
- ARBELE Limited
- Beth Bioinformatics Co., Limited
- Centre for Translational Stem Cell Biology
- The Centre for Virology, Vaccinology, and Therapeutics
- DECODE CURE Limited
- GenEditBio Limited
- Great Bay Bio
- Hong Kong Universal Biologicals Company Limited
- Immuno Cure Holding (HK) Limited
- The Institute for Innovation, Translation and Policy Research (ITPR)
- LEE'S PHARMACEUTICAL (HK) LIMITED
- Serilink Biotechnology Company Limited
- Xiaomo Biotech Limited
- XUXIN (HongKong) Biotechnology Co., Limited
- Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited
Hashtag: #HKSTP
The issuer is solely responsible for the content of this announcement.
References
- ^ Media OutReach Newswire (www.media-outreach.com)
Authors: Hong Kong Science and Technology Parks Corporation
Read more https://www.media-outreach.com/news/hong-kong-sar/2025/06/17/389454/
